Home › Intestinal Cancer › Texas › Houston
Intestinal Cancer clinical trials in Houston, TX
4 studies for Intestinal Cancer are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- Oncology Consultants P.A., Houston
- Oncology Consultants P.A., Houston
- Texas Oncology - Gulf Coast, Houston
- and 7 more
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- MD Anderson, Houston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- MD Anderson Cancer Center, Houston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
About Intestinal Cancer
There are five types of small intestine cancer. Find out how your diet and health history can affect your risk. Learn about intestinal cancer here.
More about Intestinal Cancer on MedlinePlus
Intestinal Cancer trials in other cities
- Boston, MA4 studies
- New York City, NY3 studies
- Indianapolis, IN3 studies
- Arlington, VA3 studies
- Nashville, TN3 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)121 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia85 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer61 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.